

Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline

Published: 2010-JUN-24

Pages: 596

Format: PDF

Price: 3400 USD (Single User License)

Description

This report comprises defined and up to date development strategies for 145 cancer peptide drugs within the portfolio of 103 investigators, from Ceased to Marketed. The report extensively analyses 125 identified targets of peptide drugs, organized into 103 drug target strategies, and assesses them in 52 different cancer indications.

The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Alternative binding peptide molecules, derived from combinatorial scaffold libraries, are now challenging traditional antibodies. This report identifies the competitive terrain for cancer therapeutic peptides to be wide open from a compound perspective and the opportunity for peptide drugs to challenge other biologicals such as antibodies is real and significant.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

- * Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- * Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- * Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- * Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- * Supporting development of integrative molecule, pathway and disease area strategies
- * Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any cancer peptide drug to ensure that the optimal market conditions exist by the time the product is commercialized.

Table of Contents

1	Executive Summary	3
2	About Cancer Highlights™	4
2.1	Cancer Focus Areas	4
2.2	Subscribe Today and Start Saving	5
2.2.1	Type of License	5
2.3	BioSeeker Group's Oncology Team	5
3	Methodology	6
3.1	Cancer Highlights™ Five Pillar Assessment	6
4	Table of Contents	8
4.1	List of Figures	17
4.2	List of Tables	17
5	Introduction	24
5.1	The Scope of this Report	24
5.2	The Competitive Advantage and Disadvantage of Peptide Drugs	26

BioMarket Group - A Global Online Aggregator of Life Science Market Research

5.3	Definitions	28	
5.4	Abbreviations	28	
6	Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment	29	
6.1	Drug Repositioning in Oncology	29	
6.2	Introduction to Peptide Therapeutic Targets in Oncology	30	
6.2.1	Catalytic Activity Targets	33	
6.2.2	Chaperone Activity Targets	34	
6.2.3	Chemokine Activity Targets	36	
6.2.4	Cytokine Activity Targets	40	
6.2.5	Cytoskeletal Protein Binding Targets	42	
6.2.6	DNA Binding Targets	43	
6.2.7	DNA Topoisomerase Activity Targets	44	
6.2.8	G-protein Coupled Receptor Activity Targets	45	
6.2.9	Growth Factor Activity Targets	63	
6.2.10	Heat Shock Protein Activity Targets	64	
6.2.11	Hormone Activity Targets	65	
6.2.12	Isomerase Activity Targets	66	
6.2.13	Kinase Activity Targets	67	
6.2.14	Kinase Binding Targets	69	
6.2.15	Kinase Regulator Activity Targets	70	
6.2.16	Ligand-dependent Nuclear Receptor Activity Targets	72	
6.2.17	Metalloproteinase Activity Targets	75	
6.2.18	Molecular Function Unknown Targets	81	
6.2.19	Oxidoreductase Activity Targets	87	
6.2.20	Peptide Hormone Targets	88	
6.2.21	Protease Inhibitor Activity Targets	90	
6.2.22	Protein Binding Targets	91	
6.2.23	Protein Serine/Threonine Kinase Activity Targets	93	
6.2.24	Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets	103	
6.2.25	Protein-tyrosine Kinase Activity Targets	104	
6.2.26	Receptor Activity Targets	107	
6.2.27	Receptor Binding Targets	130	
6.2.28	Receptor Signaling Complex Scaffold Activity Targets	132	
6.2.29	Receptor Signaling Protein Serine/Threonine Kinase Activity Targets	135	
6.2.30	Receptor Signaling Protein Serine/Threonine Kinase Activity Targets	136	
6.2.31	RNA Binding Targets	137	
6.2.32	RNA-directed DNA Polymerase Activity Targets	138	
6.2.33	Serine-type Peptidase Activity Targets	139	
6.2.34	Signal Transducer Activity Targets	142	
6.2.35	Structural Molecule Activity Targets	144	
6.2.36	T Cell Receptor Activity Targets	145	
6.2.37	Transcription Factor Activity Targets	146	
6.2.38	Transcription Regulator Activity Targets	153	
6.2.39	Transferase Activity Targets	154	
6.2.40	Transmembrane Receptor Activity Targets	155	
6.2.41	Transmembrane Receptor Protein Tyrosine Kinase Activity Targets	159	
6.2.42	Ubiquitin-specific Protease Activity Targets	170	
6.2.43	Virus Targets	171	
6.3	The Cancer Genome Project and Cancer Peptide Targets	172	
6.3.1	Cancer Peptide Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer	172	
6.4	Structure-based Drug Design in Cancer Peptide Therapeutics is Stimulated by Available Structure Data on Biological Targets	177	
6.5	Target-Target Interactions among Identified Targets of Peptide Drugs	179	
6.6	The Drug-Target Interactome	183	
6.7	Protein Expression Levels of Identified Targets of Cancer Peptide Drugs	187	
6.8	Pathway Assessment of Peptide Therapeutic Targets in Oncology	190	
6.8.1	Tools for Analysis of Cancer Pathways	191	
6.8.2	Pathway Assessment	192	
7	Emerging New Products to Established Ones: Drug Target Strategies of Peptides by their Highest Stage of Development in Oncology		
220			
7.1	Drug Target Strategies of Terminated Peptide Drugs in Oncology	222	
7.2	Marketed: New and Unique Drug Target Strategies of Peptide Drugs in Oncology	225	
7.3	Phase III Clinical Development: New and Unique Drug Target Strategies of Peptide Drugs in Oncology	227	
7.4	Phase II Clinical Development: New and Unique Drug Target Strategies of Peptide Drugs in Oncology	228	
7.5	Phase I Clinical Development: New and Unique Drug Target Strategies of Peptide Drugs in Oncology	230	
7.6	Preclinical Development: New and Unique Drug Target Strategies of Peptide Drugs in Oncology	232	
7.7	No Development Data: New and Unique Drug Target Strategies of Peptide Drugs in Oncology	235	
7.8	Development Profiles of All Peptide Drugs in Oncology	236	
7.9	The Competition Through Close Mechanistic Approximation of Cancer Peptide Drugs	245	
8	Selecting Cancer Indications for Peptide Drugs	247	
8.1	Acute Myelogenous Leukemia	250	
8.2	Benign prostatic hyperplasia	251	
8.3	Bladder Cancer	252	
8.4	Bone Cancer	253	
8.5	Brain Cancer	254	
8.6	Breast Cancer	255	
8.7	Cancer Diagnosis	257	

BioMarket Group - A Global Online Aggregator of Life Science Market Research

8.8	Carcinoid 258	
8.9	Carcinoid Syndrome	258
8.10	Cervical Cancer	258
8.11	Chemotherapy-induced Alopecia	259
8.12	Chemotherapy-induced Anemia	259
8.13	Chemotherapy-induced Bone Marrow Injury (general)	260
8.14	Chemotherapy-induced GI Injury	261
8.15	Chemotherapy-induced Injury (general)	262
8.16	Chemotherapy-induced Mucositis	262
8.17	Chemotherapy-induced Nausea and Vomiting	264
8.18	Chemotherapy-induced Neutropenia	264
8.19	Chemotherapy-induced Thrombocytopenia	264
8.20	Chronic Lymphocytic Leukemia	265
8.21	Chronic Myelogenous Leukemia	266
8.22	Colorectal Cancer	267
8.23	Endometrial Cancer	269
8.24	Fallopian Tube Cancer	269
8.25	Gastrointestinal Cancer (general)	270
8.26	Gastrointestinal Stomach Cancer	271
8.27	Head and Neck Cancer	272
8.28	Liver Cancer	273
8.29	Lung Cancer (general)	275
8.30	Lymphoma (general)	276
8.31	Melanoma	277
8.32	Mesothelioma	279
8.33	Myelodysplastic Syndrome	280
8.34	Myeloma	281
8.35	Myoma	282
8.36	Neuroblastoma	282
8.37	non-Hodgkin's Lymphoma	282
8.38	Non-Small Cell Lung Cancer	283
8.39	Oesophageal Cancer	285
8.40	Ovarian Cancer	286
8.41	Pancreatic Cancer	288
8.42	Peritoneal Cancer	289
8.43	Prostate Cancer	290
8.44	Renal Cancer	293
8.45	Sarcoma (general)	294
8.46	Small Cell Lung Cancer	295
8.47	Soft Tissue Sarcoma	296
8.48	Solid Tumor	297
8.49	Squamous Cell Cancer	297
8.50	Thyroid Cancer	297
8.51	Unspecified	298
8.52	Vaccine adjunct	300
9	Pipeline and Portfolio Planning: Competitive Benchmarking of the Peptide Drug Pipeline in Oncology by Investigator	301
9.1	Competitive Fall-Out Assessment	301
9.2	Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change	303
9.3	Abbott	304
9.4	Accelaron Pharma	308
9.5	Aeterna Zentaris	311
9.6	Affymax	317
9.7	Aileron Therapeutics	321
9.8	Allostera	323
9.9	Ambrilia Biopharma	325
9.10	Amgen	328
9.11	Anchor Therapeutics	332
9.12	AngioChem	335
9.13	Angstrom Pharmaceuticals	338
9.14	AplaGen Biopharmaceuticals	341
9.15	ApopLogic Pharmaceuticals	343
9.16	Apthera	346
9.17	Ardana	349
9.18	Ark Therapeutics	353
9.19	Attenuon	355
9.20	AVI BioPharma	358
9.21	Baxter International	361
9.22	BioAlliance Pharma	364
9.23	Biokine Therapeutics	366
9.24	CanBas	369
9.25	Cancer Innovations	372
9.26	Cancer Research Technology	375
9.27	CDG Therapeutics	381
9.28	Celecure	384
9.29	Celldex Therapeutics	386
9.30	Chemokine Therapeutics	389

9.31	Compugen	392
9.32	Curaxis Pharmaceutical	394
9.33	Cyclacel	397
9.34	Daiichi Sankyo	399
9.35	Dendreon	401
9.36	Diatos	404
9.37	Eli Lilly	407
9.38	Endo Pharmaceuticals	410
9.39	Enkam Pharmaceuticals	413
9.40	EntreMed	416
9.41	Esperance Pharmaceuticals	419
9.42	Generex	421
9.43	GENova Biotherapeutics	423
9.44	Genzyme	425
9.45	GlaxoSmithKline	428
9.46	Gliknik	431
9.47	GP Pharm	433
9.48	Gryphon Therapeutics	437
9.49	Hoffmann-La Roche	439
9.50	ImmuneRegen Biosciences	442
9.51	ImmunoCellular Therapeutics	444
9.52	Immunomedics	446
9.53	Immunotope	448
9.54	ImmuPharma	451
9.55	Innovive	453
9.56	ISA Pharmaceuticals	456
9.57	Johnson & Johnson	459
9.58	Karyon-CTT	463
9.59	Lee's Pharmaceutical	466
9.60	Mannkind	469
9.61	Marillion Pharmaceuticals	471
9.62	MBiotec	474
9.63	Mediolanum	476
9.64	MolMed	479
9.65	Nektar Therapeutics	483
9.66	Nemod Biotherapeutics	486
9.67	Nidus Laboratories	489
9.68	Non-industrial Sources	492
9.69	Norwood Abbey	498
9.70	Novartis	501
9.71	NPS Pharmaceuticals	504
9.72	OncoTherapy Science	507
9.73	Oncothyreon	510
9.74	Pepscan Therapeutics	514
9.75	PepTx	516
9.76	PharmaGap	519
9.77	Pharmexa	522
9.78	Q Chip	525
9.79	QLT	528
9.80	Raptor Pharmaceutical	531
9.81	Receptor BioLogix	535
9.82	SciClone Pharmaceuticals	538
9.83	Serometrix	541
9.84	Shire	543
9.85	Soligenix	546
9.86	Spectrum Pharmaceuticals	549
9.87	Thallion Pharmaceuticals	551
9.88	Therion Biologics	554
9.89	Theryte	557
9.90	Tigris Pharmaceuticals	560
9.91	Unigene	562
9.92	United Biomedical	565
9.93	Vaxil BioTherapeutics	567
9.94	Vaxon Biotech	570
9.95	VaxOnco	573
9.96	Vical	576
9.97	Xigen	579
9.98	Zealand Pharmaceuticals	581
9.99	Zelos Therapeutics	584
9.100	Zensun	586
10	Disclaimer	588
11	Drug Index	589
12	Company Index	593

4.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Peptide Drugs in Oncology 182

BioMarket Group - A Global Online Aggregator of Life Science Market Research

Figure 2: The Drug-Target Interactions of Cancer Peptide Drugs - Large Cluster	184
Figure 3: The Drug-Target Interactions of Cancer Peptide Drugs - Smaller Clusters	185
Figure 4: Head-to-Head Targeting Interactions of Cancer Peptide Drugs	186

4.2 List of Tables

Table 1: Cancer Highlights™ Five Pillar Assessment	6
Table 2: Breakdown of the Included Cancer Peptide Pipeline by Stage of Development	24
Table 3: Head to Head Target Competition among Cancer Peptide Drugs	24
Table 4: Overview of Drug Target Strategy Themes	30
Table 5: Terminally Ceased Targets of Peptide Drugs in Oncology	31
Table 6: Drug Targets of Peptide Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census	173
Table 7: Identity of Cancer Peptide Drug Targets with Available Biological Structures	177
Table 8: Number of Target-Target Interactions among Targets of Peptide Drugs in Oncology	179
Table 9: Available Protein Expression Profiles of Peptide Drug Targets	187
Table 10: Pathway Summary	192
Table 11: Drug Targets without any Identified Assigned Pathways	192
Table 12: Pathway Profiles According to BioCarta of Peptide Drug Targets in Oncology	194
Table 13: Pathway Profiles According to KEGG of Peptide Drug Targets in Oncology	205
Table 14: Pathway Profiles According to NetPath of Peptide Drug Targets in Oncology	217
Table 15: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness	220
Table 16: Top Competitive Target Strategies of Peptide Drugs in Oncology	221
Table 17: Target Strategies of Terminated Peptide Drugs in Oncology	223
Table 18: New and Unique Target Strategies of Marketed Peptide Drugs in Oncology	225
Table 19: The Competition Through Close Mechanistic Approximation Between Marketed Peptide Drugs in Cancer	226
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Peptide Drugs in Oncology	227
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Peptide Drugs in Cancer	227
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Peptide Drugs in Oncology	228
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Peptide Drugs in Cancer	229
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Peptide Drugs in Oncology	230
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Peptide Drugs in Cancer	231
Table 26: New and Unique Target Strategies in Preclinical Development of Peptide Drugs in Oncology	232
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Peptide Drugs in Cancer	233
Table 28: New and Unique Target Strategies in Unknown Developmental Stage of Peptide Drugs in Oncology	235
Table 29: The Competition Through Close Mechanistic Approximation Between Peptide Drugs with No Developmental Data in Cancer	235
Table 30: The Progression, Maturity and Competitive Comparison of Target Strategies of Peptide Drugs in Oncology	236
Table 31: The Competition Through Close Mechanistic Approximation Among All Peptide Drugs in Cancer	245
Table 32: Indication Selection Competitive Summary of Peptide Drugs by Cancer Indication	248
Table 33: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Acute Myelogenous Leukemia	250
Table 34: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Benign prostatic hyperplasia	251
Table 35: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Bladder Cancer	252
Table 36: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Bone Cancer	253
Table 37: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Brain Cancer	254
Table 38: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Breast Cancer	255
Table 39: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs	256
Table 40: Target Strategy Development Profiles of Peptide Compounds for Cancer Diagnosis	257
Table 41: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Carcinoid	258
Table 42: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Carcinoid Syndrome	258
Table 43: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Cervical Cancer	258
Table 44: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Alopecia	259
Table 45: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Anemia	259
Table 46: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Bone Marrow Injury (general)	260
Table 47: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced GI Injury	261
Table 48: The Competition through Close Mechanistic Approximation between Chemotherapy-induced GI Injury Drugs	261
Table 49: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Injury (general)	262
Table 50: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Mucositis	262
Table 51: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Nausea and Vomiting	264
Table 52: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Neutropenia	264
Table 53: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Thrombocytopenia	264
Table 54: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chronic Lymphocytic Leukemia	265
Table 55: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chronic Myelogenous Leukemia	266
Table 56: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Colorectal Cancer	267
Table 57: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Endometrial Cancer	269
Table 58: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Fallopian Tube Cancer	269
Table 59: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Gastrointestinal Cancer (general)	270
Table 60: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Gastrointestinal Stomach Cancer	271
Table 61: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Head and Neck Cancer	272
Table 62: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Liver Cancer	273
Table 63: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs	274
Table 64: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Lung Cancer (general)	275
Table 65: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Lymphoma (general)	276
Table 66: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Melanoma	277
Table 67: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Mesothelioma	279
Table 68: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Myelodysplastic Syndrome	280
Table 69: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Myeloma	281
Table 70: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Myoma	282
Table 71: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Neuroblastoma	282

BioMarket Group - A Global Online Aggregator of Life Science Market Research

Table 72: Target Strategy Development Profiles of Peptide Drugs for the Treatment of non-Hodgkin's Lymphoma	282
Table 73: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Non-Small Cell Lung Cancer	283
Table 74: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs	284
Table 75: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Oesophageal Cancer	285
Table 76: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Ovarian Cancer	286
Table 77: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs	287
Table 78: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Pancreatic Cancer	288
Table 79: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs	289
Table 80: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Peritoneal Cancer	289
Table 81: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Prostate Cancer	290
Table 82: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs	291
Table 83: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Renal Cancer	293
Table 84: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Sarcoma (general)	294
Table 85: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Small Cell Lung Cancer	295
Table 86: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Soft Tissue Sarcoma	296
Table 87: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Solid Tumor	297
Table 88: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Squamous Cell Cancer	297
Table 89: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Thyroid Cancer	297
Table 90: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Unspecified	298
Table 91: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs	300
Table 92: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Vaccine adjunct	300
Table 93: Example of a Competitive Fall-Out Table (Modified, Gonadotropin-releasing hormone receptor)	302
Table 94: Summary Table of Changes in the Competitive Landscape of Peptide Drug Development in Oncology	303
Table 95: Abbott's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	304
Table 96: Acceleron Pharma's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	308
Table 97: Aeterna Zentaris' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	311
Table 98: Affymax's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	317
Table 99: Aileron Therapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	321
Table 100: Allostera's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	323
Table 101: Ambrilia Biopharma's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	325
Table 102: Amgen's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	328
Table 103: Anchor Therapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	332
Table 104: AngioChem's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	335
Table 105: Angstrom Pharmaceuticals' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	338
Table 106: AplaGen Biopharmaceuticals' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	341
Table 107: ApopLogic Pharmaceuticals' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	343
Table 108: Aphera's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	346
Table 109: Ardana's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	349
Table 110: Ark Therapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	353
Table 111: Attenuon's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	355
Table 112: AVI BioPharma's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	358
Table 113: Baxter International's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	361
Table 114: BioAlliance Pharma's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	364
Table 115: Biokine Therapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	366
Table 116: CanBas' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	369
Table 117: Cancer Innovations' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	372
Table 118: Cancer Research Technology's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	375
Table 119: CDG Therapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	381
Table 120: Celecure's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	384
Table 121: Celldex Therapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	386
Table 122: Chemokine Therapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	389
Table 123: Compugen's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	392
Table 124: Curaxis Pharmaceutical's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	394
Table 125: Cyclacel's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	397
Table 126: Daiichi Sankyo's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	399
Table 127: Dendreon's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	401
Table 128: Diatos' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	404
Table 129: Eli Lilly's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	407
Table 130: Endo Pharmaceuticals' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	410
Table 131: Enkam Pharmaceuticals' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	413
Table 132: EntreMed's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	416
Table 133: Esperance Pharmaceuticals' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	419
Table 134: GenereX's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	421
Table 135: GENova Biotherapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	423
Table 136: Genzyme's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	425
Table 137: GlaxoSmithKline's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	428
Table 138: Gliknik's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	431
Table 139: GP Pharm's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	433
Table 140: Gryphon Therapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	437
Table 141: Hoffmann-La Roche's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	439
Table 142: ImmuneRegen Biosciences' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	442
Table 143: ImmunoCellular Therapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	444
Table 144: Immunomedics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	446
Table 145: Immunotope's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	448
Table 146: ImmuPharma's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	451
Table 147: Innovive's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	453

BioMarket Group - A Global Online Aggregator of Life Science Market Research

Table 148: ISA Pharmaceuticals' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	456
Table 149: Johnson & Johnson's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	459
Table 150: Karyon-CTT's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	463
Table 151: Lee's Pharmaceutical's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	466
Table 152: Mannkind's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	469
Table 153: Marillion Pharmaceuticals' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	471
Table 154: MBIotec's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	474
Table 155: Mediolanum's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	476
Table 156: MolMed's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	479
Table 157: Nektar Therapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	483
Table 158: Nemed Biotherapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	486
Table 159: Nidus Laboratories' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	489
Table 160: Non-industrial Sources' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	492
Table 161: Norwood Abbey's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	498
Table 162: Novartis' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	501
Table 163: NPS Pharmaceuticals' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	504
Table 164: OncoTherapy Science's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	507
Table 165: Oncothyreon's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	510
Table 166: Pepscan Therapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	514
Table 167: PepTx's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	516
Table 168: PharmaGap's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	519
Table 169: Pharmexa's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	522
Table 170: Q Chip's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	525
Table 171: QLT's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	528
Table 172: Raptor Pharmaceutical's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	531
Table 173: Receptor BioLogix's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	535
Table 174: SciClone Pharmaceuticals' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	538
Table 175: Serometrix's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	541
Table 176: Shire's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	543
Table 177: Soligenix's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	546
Table 178: Spectrum Pharmaceuticals' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	549
Table 179: Thallion Pharmaceuticals' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	551
Table 180: Therion Biologics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	554
Table 181: Theyte's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	557
Table 182: Tigris Pharmaceuticals' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	560
Table 183: Unigene's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	562
Table 184: United Biomedical's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	565
Table 185: Vaxil BioTherapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	567
Table 186: Vaxon Biotech's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	570
Table 187: VaxOnco's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	573
Table 188: Vical's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	576
Table 189: Xigen's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	579
Table 190: Zealand Pharmaceuticals' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	581
Table 191: Zelos Therapeutics' Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	584
Table 192: Zensun's Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out	586

Ordering

Order Online - <http://www.biomarketgroup.com/market-research-report/commercializing-peptides-in-oncology-a-decision-support-tool-for-optimizing-the-pipeline.html>

Order by Fax - using the form below

Order by Post - print the order form below and send to:

BioMarket Group
Björnåsvägen 21
11419 STOCKHOLM
SWEDEN

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit

<http://www.biomarketgroup.com/market-research-report/contacts/>

Order Information

Please verify that the product information is correct:

Product Name: **Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline**

Web Address: <http://www.biomarketgroup.com/market-research-report/commercializing-peptides-in-oncology-a-decision-support-tool-for-optimizing-the-pipeline.html>

Format: PDF

Price: 3400 USD (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 USD.

Delivery within Sweden is subject to VAT at 25%.

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: _____

Name: _____

Email Address:* _____

Job Title: _____

Organization: _____

EU companies must supply: VAT / BTW / MOMS

MWST / IVA / FPA number:

Address: _____

Zip Code: _____

City: _____

State: _____

Country: _____

Phone Number: _____

Fax Number: _____

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:**
- American Express
 - Master Card
 - Visa

Cardholder Name: _____

Expiry Date (MM/YY): _____

Card Number: _____

CVV Number: _____

- Pay by check:**

Please post the check, accompanied by this form, to:

BioMarket Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN

- Pay by wire transfer:** Please transfer funds to:

Account number: 43521169

Swift code: HANDSESS

IBAN number: SE74 6000 0000 0000 4352 1169

Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please supply purchase order number if needed:

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioMarket Group you are agreeing to our Terms and Conditions at

<http://www.biomarketgroup.com/market-research-report/biomarket-group-full-terms-and-conditions/>

Please fax this form to: +46-8-56849191